|
Volumn 166, Issue 8, 2009, Pages 937-938
|
Discontinuation of quetiapine from an NIMH-funded trial due to serious adverse events
a a a a a a a a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ARIPIPRAZOLE;
ATYPICAL ANTIPSYCHOTIC AGENT;
OLANZAPINE;
QUETIAPINE;
RISPERIDONE;
DIBENZOTHIAZEPINE DERIVATIVE;
NEUROLEPTIC AGENT;
ADULT;
AGED;
BIPOLAR DISORDER;
CARDIOVASCULAR DISEASE;
CEREBROVASCULAR DISEASE;
CLINICAL TRIAL;
COMORBIDITY;
DEATH;
DEMENTIA;
DEPRESSION;
DRUG SAFETY;
DRUG WITHDRAWAL;
FOOD AND DRUG ADMINISTRATION;
HOSPITALIZATION;
HUMAN;
INFECTION;
LETTER;
MAJOR CLINICAL STUDY;
MENTAL DISEASE;
MULTIVARIATE LOGISTIC REGRESSION ANALYSIS;
PNEUMONIA;
POSTTRAUMATIC STRESS DISORDER;
PRIORITY JOURNAL;
PSYCHOPHARMACOTHERAPY;
PSYCHOSIS;
RISK ASSESSMENT;
SCHIZOPHRENIA;
SEIZURE;
SIDE EFFECT;
SUICIDE ATTEMPT;
TREATMENT OUTCOME;
FINANCIAL MANAGEMENT;
MAJOR DEPRESSION;
NATIONAL HEALTH ORGANIZATION;
PSYCHOLOGICAL ASPECT;
RANDOMIZED CONTROLLED TRIAL;
REGRESSION ANALYSIS;
STATISTICS;
UNITED STATES;
ANTIPSYCHOTIC AGENTS;
DEPRESSIVE DISORDER, MAJOR;
DIBENZOTHIAZEPINES;
HUMANS;
NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.);
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
REGRESSION ANALYSIS;
RESEARCH SUPPORT AS TOPIC;
UNITED STATES;
|
EID: 68149175328
PISSN: 0002953X
EISSN: 15357228
Source Type: Journal
DOI: 10.1176/appi.ajp.2009.09040501 Document Type: Letter |
Times cited : (8)
|
References (3)
|